Literature DB >> 29118352

Thyroid cancer: Lenvatinib - beyond trials.

Claire Greenhill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29118352     DOI： 10.1038/nrendo.2017.149

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  1 in total

1.  Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice.

Authors:  Amandine Berdelou; Isabelle Borget; Yann Godbert; Thierry Nguyen; Marie-Eve Garcia; Cécile N Chougnet; Aurélie Ferru; Camille Buffet; Olivier Chabre; Olivier Huillard; Sophie Leboulleux; Martin Schlumberger
Journal:  Thyroid       Date:  2017-11-27       Impact factor: 6.568
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.